Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-17P, also known as "RNA, U6 small nuclear 17, pseudogene," is a noncoding RNA gene classified as a pseudogene of the U6 small nuclear RNA family. U6 small nuclear RNA (snRNA) plays a crucial role in mRNA splicing as a component of the spliceosome, but as a pseudogene, RNU6-17P does not encode functional RNA and is not transcribed as a biologically active molecule[5][1]. U6 snRNA pseudogenes are generated by retrotransposition processes and are present as non-functional genomic relics, lacking roles in splicing or other cellular mechanisms[5]. There is no evidence that RNU6-17P serves as a therapeutic target, nor is it associated with drug interactions, biomarkers, or safety concerns. Pseudogenes like RNU6-17P may be used as markers of retrotransposition activity in comparative genomics studies[5]. The "is_incorrect" flag is marked true because this entry refers to a pseudogene rather than a functional therapeutic target, receptor, or conventional drug target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 17, pseudogene (RNU6-17P).